Log in | Register

E-mail
Company Name

Dr. Reddy’s Launches Authorized Generic Version of Imitrex Tablets

Featured In: Legal  |  GlaxoSmithKline

Monday, December 1, 2008

Share
Loading...


Dr. Reddy’s Laboratories (NYSE:RDY) today announced that it has launched the authorized generic version of GlaxoSmithKline’s Imitrex (sumatriptan succinate) tablets 25mg, 50mg, and 100mg in the United States. Dr. Reddy’s is the first company to launch an authorized generic version of Imitrex tablets in the US market.
In October 2006, the Company announced that it had settled patent litigation with GlaxoSmithKline relating to sumatriptan succinate tablets, the generic version of GlaxoSmithKline Imitrex tablets. The specific financial terms and conditions of the settlement have not been disclosed.

GlaxoSmithKline Imitrex® tablets, which are indicated for the acute treatment of migraine attacks in adults, had U.S. sales of $1.29 billion for the 12 month period ending December, 2007 according to IMS.
Join the Discussion
Rate Article:  Average 0 out of 5
register or log in to comment on this article!

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

Blogs

The Importance of Fundamentals

The Importance of Fundamentals

Aug 31 | Girish Malhotra, PE, President, EPCOT International

Globally, Johnson & Johnson is known for its integrity and product quality. A few years ago they handled the Tylenol situation extremely well and were commended for it. It is astounding that the year 2010 has become a nightmare for them.  
The Quality Control Unit: Invertebrates Need Not Apply

The Quality Control Unit: Invertebrates Need Not Apply

Aug 30 | The QA Pharm

The Quality Control Unit (QCU) is the only pharmaceutical function that has a job description codified in the CGMP regulations. Don’t you find this remarkable? In fact, an entire section is devoted to describing the responsibility of the QCU and how it is to operate within the organization—namely independently.        

Multimedia

Timothy Cote - Office of Orphan Products Development

Aug 13 | Root

From approving medicines to treating snake bites to Cystic Fibrosis - Dr. Tim Cote describes a special office at the FDA, designed to address needs of people with rare diseases. Timothy Cote, M.D. - Director, Office of Orphan Products Development
Charles River Labs On WuXi PharmaTech Acquisition

Charles River Labs On WuXi PharmaTech Acquisition

May 25 | Video

Charles Rivers Laboratories International Chief Officer talks about the recent WuXi PharmaTech acquisition
Biogen Idec - 2010 Facility of the Year Award Winner - Operational Excellence

Biogen Idec - 2010 Facility of the Year Award Winner - Operational Excellence

Apr 27 | Video

Peter Flinn, Biogen Idec's Senior Director, Global Project Engineering talks to Pharmaceutical Processing's Editor-In-Chief Mike Auerbach about the company's Large-Scale Manufacturing Technology Map Project in Research Triangle Park, North Carolina. The project won the 2010 Operational...
MannKind Corporation - 2010 Facility of the Year Award Winner - Equipment & Process Innovation

MannKind Corporation - 2010 Facility of the Year Award Winner - Equipment & Process Innovation

Apr 28 | Video

Juergen Martens, Ph,D. MannKind Corporation's Corporate Vice President and Chief Technical Officer talks to Pharmaceutical Processing's Editor-In-Chief Mike Auerbach durng INTERPHEX2010 about the company's Technosphere Insulin Manufacturing Facility located in Danbury, Connecticut. The...